Regulation of the human apolipoprotein AIV gene expression in transgenic mice  by Baralle, M et al.
Regulation of the human apolipoprotein AIV gene expression in
transgenic mice
M. Barallea, L. Vergnesb, A.F. Muroa, M.M. Zakinb, F.E. Barallea;*, A. Ochoab
aMolecular Pathology, International Centre for Genetic Engineering and Biotechnology, Padriciano 99, 34012 Trieste, Italy
bUniteŁ d’Expression des GeØnes Eucaryotes, Institut Pasteur, 28 rue du Dr. Roux, Paris, France
Received 9 January 1999
Abstract The apolipoprotein (Apo) AI-CIII-AIV gene cluster
has a complex pattern of gene expression that is modulated by
both gene- and cluster-specific cis-acting elements. In particular
the regulation of Apo AIV expression has been previously studied
in vivo and in vitro including several transgenic mouse lines but a
complete, consistent picture of the tissue-specific controls is still
missing. We have analysed the role of the Apo AIV 3P flanking
sequences in the regulation of gene expression using both in vitro
and in vivo systems including three lines of transgenic mice. The
transgene consisted of a human fragment containing 7 kb of the
5P flanking region, the Apo AIV gene itself and 6 kb of the 3P
flanking region (37+6 Apo AIV). Accurate analysis of the Apo
AIV mRNA levels using quantitative PCR and Northern blots
showed that the 37+6 kb Apo AIV fragment confers liver-
specific regulation in that the human Apo AIV transgene is
expressed at approximately the same level as the endogenous
mouse Apo AIV gene. In contrast, the intestinal regulation of the
transgene did not follow the pattern observed with the
endogenous gene although it produced a much higher intestinal
expression following the accepted human pattern. Therefore, this
animal model provides an excellent substrate to design ther-
apeutic protocols for those metabolic derangements that may
benefit from variations in Apo AIV levels and its anti-atherogenic
effect.
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1. Introduction
The gene encoding apolipoprotein (Apo) AIV can be found
with those encoding Apo AI and CIII in a cluster of 17 kb on
chromosome 11 [1]. The identi¢cation of rearrangements of
this cluster in patients su¡ering from premature atherosclero-
sis and epidemiological and clinical data have clearly demon-
strated the importance of this chromosomal region in the
regulation of lipid metabolism [2^4]. The Apo AI and AIV
genes are transcribed in the same direction whereas the Apo
CIII gene, located between the two, is transcribed in the op-
posite direction. The Apo AI and CIII genes have been re-
ported to be primarily expressed in liver and intestine, where-
as the Apo AIV gene is expressed mainly in the intestine with
varying degrees of liver expression in di¡erent species [5^8].
Transgenic and knockout mice together with transient expres-
sion in tissue culture cells have provided extensive information
regarding Apo AI-CIII-AIV gene cluster regulation, identify-
ing a series of cis-acting elements which modulate their ex-
pression. Fig. 1 shows the organisation of the human Apo AI-
CIII-AIV gene cluster. Liver control elements for Apo AI and
CIII genes reside in the 5P £anking region, whereas an intes-
tinal control region thought to regulate the expression of the
entire gene cluster at this locus is located in the Apo CIII-AIV
intergenic region, close to the Apo CIII promoter [9^12].
The regulation of Apo AIV expression has been previously
studied in vivo and in vitro including several transgenic mouse
lines [8,9,13^15] but a complete, consistent picture of the tis-
sue-speci¢c controls is still missing. Particularly, the elements
that regulate Apo AIV gene expression in both man and mice
need further de¢nition. The transgenic mouse experiments and
some direct tissue measurements point to minimal expression
of Apo AIV mRNA in liver with the main site of expression
being the intestine [6]. However, there are reports of variable
Apo AIV mRNA intestine/liver ratios even using the same
transgene [9,13]. These contradictory results may have their
origin not only in the di¡erent methodologies used to measure
Apo AIV mRNA, which have included dot blot hybridisation
[7], RNA excess solution hybridisation [16] and Northern blot
quanti¢cation [13], but also in the known variability of Apo
AIV RNA levels with di¡erent physiological conditions
[8,13,17] and genetic backgrounds [15]. The latter has been
shown in inbred mice to be responsible for up to an 11-fold
variation of Apo AIV mRNA levels in the liver. Furthermore,
it has been shown that the contribution of the liver towards
the Apo AIV pool in plasma is approximately equal to that of
the intestine [18] and that hormones that in£uence Apo AIV
levels in plasma have been found to a¡ect Apo AIV mRNA
levels in a tissue-selective manner with the liver showing a
much tighter regulation than the intestine [19^21]. All these
data taken together point to an essential role of the liver in
Apo AIV synthesis and metabolism.
In this paper we analyse the role of Apo AIV 3P £anking
sequences in the regulation of gene expression using both in
vitro and in vivo systems including three lines of transgenic
mice. The transgene consisted of a human fragment contain-
ing 7 kb of the 5P £anking region, the Apo AIV gene itself and
6 kb of the 3P £anking region (37+6 kb AIV fragment).
Accurate analysis of the Apo AIV RNA levels using quanti-
tative PCR and Northern blots showed that the 37+6 kb AIV
fragment confers liver-speci¢c regulation in that the human
Apo AIV transgene is expressed at approximately the same
level as the endogenous mouse Apo AIV gene. This is not the
case for the intestinal expression of the transgene indicating
either that there may be important di¡erences between mouse
and human Apo AIV gene regulation or that the fragment
used for the construction of the transgenic animal is missing
essential cis-acting regulatory elements.
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2. Materials and methods
2.1. Isolation of transgene genomic fragment
Two partially overlapping clones spanning the Apo AIV gene and
£anking regions, clone V59 and clone V63, have been previously iso-
lated [22]. A BamHI fragment, containing the Apo AIV 37274/+67
fragment, was excised from clone V63 and cloned into pBluescript II
KS. This was in turn cut with SphI (genomic site) and HindIII
(plasmid), into which we introduced the genomic fragment excised,
using the same restriction sites, from clone V59. Finally we cloned a
HindIII (genomic)-SalI (plasmid) fragment obtained again from clone
V59 into the pBluescript II KS clone cut with the same restriction
enzymes (Fig. 1), generating the transgene genomic fragment 37+6
Apo AIV.
2.2. Construction of expression vectors
The construction of plasmids p389/+67 Apo IV/CAT 6, p33870/
+67 Apo IV/CAT 6 and p37274/+67 Apo IV/CAT 6 has been de-
scribed in [23]. The addition of 6 kb of the 3P Apo AIV £anking
sequence was carried for the p389/+67 Apo IV/CAT 6 and
p33870/+67 Apo IV/CAT 6 constructs by the insertion of a Kpn-
Kpn fragment excised from the 37/+6 Apo AIV plasmid into the
Kpn site in the polylinker of pBLCAT 6. The addition of the 6 kb
Apo AIV 3P £anking region for p37274/+67 Apo IV/CAT 6 was
performed by digestion of the p33870/+67 Apo IV/CAT 6+3P with
NruI/PvuI and subsequent cloning into and p37274/+67 Apo IV/CAT
6 cut with the same enzymes.
2.3. Cell culture and transient expression assays
HepG2 and CaCo-2 cells (ATCC) were cultured in DMEM medium
containing 4.5 g/l glucose, supplemented with 10% foetal calf serum,
1% non-essential amino acids, 2 mM glutamine, 100 U/ml penicillin,
and 100 Wg/ml streptomycin (Gibco-BRL). Cells were plated out at a
density of 5U105 cells/6-cm dish and the media changed 3 h before
transfection. Plasmids were prepared by double banding in caesium
chloride or by Qiagen plasmid kit (Qiagen) and introduced into the
cells using DOTAP (Boehringer Mannheim) according to the manu-
facturer’s instruction. Each dish was transfected with 1 pmol of CAT
plasmid, 2.5 mg of pRSVL-gal, 0.125 pmol HNF-4 expression vector
(pMT2-HNF-4) or control plasmid (pMT2), and carrier plasmid
DNA (pBluescript II KS) up to 12.5 mg per dish. CAT assays
were performed using [14C]chloramphenicol and butyryl coenzyme
A. The relative CAT activities were normalised by L-galactosidase
activity.
2.4. Human Apo AIV transgenic mice
Transgenic mice were produced by micro-injection of the subge-
nomic Apo AIV fragment (37+6 Apo AIV) into the male pronuclei
of fertilised mouse oocytes (strain C57/6-CBA), as described [24].
Surviving oocytes were transplanted into the oviducts of pseudopreg-
nant foster mothers. Mice harbouring the transgene were detected by
Southern blotting and/or PCR analysis with the human Apo AIV
primers using DNA prepared from tail biopsies. Three human Apo
AIV transgenic mice lines were established, named 8018, 8021 and
8022. For successive experiments male and female mice were used
when they were 3^4 months of age, with a mixed genetic background
of 87.5% Swiss and 12.5% C57, and fed at libitum. Litter mates
negative for human Apo AIV were used as controls.
2.5. Southern blot analysis
Quantitative Southern blot analysis was performed using equal
amounts of EcoRI-digested DNA, prepared from tail biopsies of 3-
week-old F1 transgenic mice belonging to each pedigree [25]. Filters
were exposed overnight to XO-MAT ¢lm (Kodak) at 380‡C with an
enhancer screen. Quanti¢cation of the copy number was obtained by
densitometric scanning of the ¢lm. Hybridisation probes were gener-
ated using the EcoRI-EcoRI fragment of the Apo AIV gene via nick
translation of 50 ng of DNA by the random priming method using the
oligolabelling kit supplied by Pharmacia. Radiolabelled DNA probes
were puri¢ed from unincorporated nucleotides using Nick columns
(Pharmacia).
2.6. RNA extraction
Total cellular RNA was isolated from liver and the proximal third
of the small intestine by the guanidinium thiocyanate procedure [26].
The ¢nal pellet was then re-suspended in 200 Wl of ddH20 and treated
with RNase-free DNase I (Boehringer Mannheim), according to the
manufacturer’s instructions. RNA integrity was con¢rmed by dena-
turing formaldehyde agarose gel electrophoresis and quanti¢ed by
measuring absorbance at 260 nm. Using the primer pair for L-actin
ampli¢cation PCR was performed using 2 Wg of RNA to check that
no contaminating genomic DNA remained. The two human hepatic
and small intestine RNA samples were obtained from Clontech and
Invitrogen. Each sample derives from a di¡erent individual and is the
same used for the commercial poly(A) blots obtained from the same
suppliers.
2.7. Northern blots
20 Wg of total RNA was ¢rst denatured by 2.2 M formaldehyde and
50% formamide at 68‡C for 15 min and then run on a 1% formalde-
hyde gel. RNA was transferred to a nylon membrane (Hybond-N,
Amersham) by capillary blotting and hybridised to probes at 68‡C
under standard conditions. The mouse and human Apo AIV probes
were constructed using the same methodology as described in Section
2.5 using the ampli¢cation fragments of the respective primer pairs.
The probes were found not to cross-react. A Canberra Packard In-
stant Imager was used to quantify the mRNA levels. The GAPDH
probe was used to normalise for equal loading of RNA between lanes.
2.8. Competitive PCR
The method entailed the addition to the PCR sample of known
molar quantities of competitor DNA molecules that share the same
sequence as the ampli¢ed target (including primer recognition sites)
except for an insertion in the middle which allows resolution by gel
electrophoresis. It has been shown that in these conditions the amount
of competitor DNA yielding equal molar amounts of products gives
the initial amount of the target gene [27]. cDNAs were obtained using
the Pharmacia cDNA synthesis kit following the manufacturer’s in-
structions. 5 mg of total RNA was used in a 20 Wl reaction with oligo
dT as primer. The reaction was incubated for 1 h at 37‡C after which
the volume was brought up to 50 Wl. To compensate for variations in
the RNA isolation, quanti¢cation and tube-to-tube variation in the
RT reactions, the cDNAs used for the quanti¢cation of the mouse
and human Apo AIV mRNA were ¢rst normalised by competitive
PCR against an endogenous standard, the L-actin gene. All the sub-
sequent PCR reactions measuring the mouse and human hepatic and
intestinal Apo AIV mRNA were performed using the amount of
cDNA which produced an equivalence point of 5 pg with the L-actin
competitor. PCR was performed following the protocols of the Boehr-
inger Taq DNA polymerase. The ampli¢cations were performed on a
thermal cycler (Perkin-Elmer) using the following conditions for 30
cycles: (i) denaturation at 94‡C for 1 min, (ii) primer annealing at
56‡C for 1 min, and (iii) extension at 72‡C for 1 min. A slow anneal-
ing cycle of 32‡C every 10 min from 94 to 56‡C was added at the end
to prevent cross-hybridisation between target and competitor sequen-
ces.
2.9. Primers and competitors
Synthetic DNA oligonucleotide were purchased from Primm s.r.l.
(Milan, Italy). Their sequences (5P-3P) and utilisation are as follows.
For L-actin competitive PCR: CATGTTTGAGACCTTCAACA
(sense), ATCTCCTTCTGCATC-CTGTC (antisense). For mouse
Apo AIV competitive PCR: ACAGTTTCAGAA-GACGGATG
(sense), GTGGTCTGCATGCGCTGGA (antisense). For human
competitive PCR: ACATCTCCAGAAATCTGAAC (sense),
GGCGTTCTCCCGCA-GCACTC (antisense). For ampli¢cation of
GAPDH fragment used in the production of the GAPDH probe:
ACATGTTCCAGTATGATTCT (sense), ACGG-AAGGCCATGC-
CAGTGA (antisense)
Competitor templates for L-actin, mouse Apo AIV and human Apo
AIV were constructed by cloning the PCR cDNA product ampli¢ed
by the respective oligonucleotide pairs into Puc 18 at the SmaI site. A
20-bp oligo in the case of the mouse and human Apo AIV competitor
constructs and 200 bp of the intron sequence in the L-actin competitor
were inserted into the middle of the cloned sequence of cDNA in
order to allow resolution by gel electrophoresis.
2.10. Human Apo AIV protein expression in transgenic mice
5 Wl of 1:50 (v/v) plasma in SDS bu¡er (2% SDS, 6 mM Tris pH
6.8, 10% glycerol, 0.8 M 2-mercaptoethanol, 0.01% bromophenol
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blue) was resolved in an SDS-PAGE 7.5% polyacrylamide gel at 150
V for 2 h. The proteins were transferred to nitrocellulose (Schleicher
and Schuell) with a semidry transfer unit in the presence of 25 mM
Tris pH 6.8, 192 mM glycine, 20% methanol. After 1 h in blocking
bu¡er (PBS, 0.1% Tween 20, 5% non-fat dry milk) the membranes
were incubated for 1 h with 0.35 mg/ml of primary monoclonal hu-
man Apo AIV antibody (Boehringer Mannheim). The blots were
washed for 30 min in blocking bu¡er, incubated for 1 h with sheep
horseradish peroxidase-conjugated secondary antibodies (1:4000) di-
rected against mouse IgG, washed in blocking bu¡er and then devel-
oped using the ECL chemiluminescence system and hyper¢lm-ECL
(Amersham).
3. Results and discussion
3.1. The 3P Apo AIV £anking region in£uences transcription
levels
In the course of our studies on the Apo AI-CIII-AIV clus-
ter using intact HepG2 liver nuclei we have noticed that the
newly cloned 6-kb Apo AIV showed signi¢cant DNase-hyper-
sensitive sites. This preliminary observation was followed up
by studying the ability of three di¡erent 5P £anking region
fragments to direct reporter gene expression both in the pres-
ence and in the absence of the 6-kb Apo AIV 3P sequence in
HepG2 and CaCo-2 cells.
Fig. 2 shows that all three promoter fragments used were
able to direct transcription in HepG2 cells although the high-
est e⁄ciency was found when the regulatory region upstream
of the Apo CIII gene and all the intergenic sequence (37.2 kb
fragment) was included. This is consistent with the observa-
tion that two enhancers are present in this fragment: the Apo
CIII enhancer located 0.8 kb upstream of the cap site of this
gene [11] and the Apo CIII-AIV enhancer located 2.5 kb up-
stream of the Apo CIII gene and 4 kb upstream of the Apo
AIV gene [23]. Co-transfection with a plasmid encoding the
orphan nuclear receptor HNF-4, which has been demon-
strated to activate transcription of the Apo AIV gene in
HepG2 and CaCo-2 cells [22], increases the overall activity,
except in the 389 construct, but the e¡ect of the 3P £anking
region was still clearly visible. The results on CaCo-2 cells
were not as clear due to the fact that the three promoter
constructs showed a very weak activity, unless the orphan
receptor HNF-4 was co-transfected. In this case the pattern
was similar to that observed in HepG2, only for the two
largest promoter fragments. The promoter e⁄ciency is clearly
dependent on the 3P £anking region which down-regulates
transcription both in HepG2 (over 60% decrease in transcrip-
tion, and 50% decrease in co-transfections with HNF-4) and
CaCo-2 cells co-transfected with HNF-4 (40^60% decrease).
Furthermore, it is also clear that the regulatory e¡ect of the 3P
£anking region is independent of the control exerted by HNF-
4 whose cis-acting elements are present in the intergenic re-
gion [22]. These results indicate that Apo AIV expression
could be regulated by both 5P and 3P £anking sequences, a
phenomenon already observed in this cluster with the Apo AI
intestinal enhancer [12]. It was particularly interesting to take
this study beyond the in vitro stage as hepatic and intestinal
cell models are rather far from the tissue conditions. The only
system able to give more accurate information was the use of
transgenic animals including the 6 kb of the 3P £anking re-
gion. This element was absent in previous studies with Apo
AIV transgenic mice which had identical 5P fragments up-
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Fig. 1. Scheme representing the Apo AI-CIII-AIV gene cluster local-
ised on the human chromosome 11 (11q23-qter) along with control
elements that have been previously characterised. Arrows indicate
the direction of transcription of each of the genes. The three pro-
moters, not indicated, can be found at the 5P end of each gene as
can the hepatic enhancers for AI and CIII indicated by L. A single
intestinal enhancer, I, located in the intergenic region between Apo
CIII and AIV is thought to regulate the expression of the entire
gene cluster at this locus. Black and grey arrows correspond respec-
tively to positive and negative regulatory elements found in vitro
for Apo CIII and AIV. The positions of all the regulatory elements
are indicative. The 37+6 Apo AIV transgene fragment used in the
generation of the human Apo AIV mice is also indicated. Abbrevia-
tions for restriction sites are as follows: B, BamHI; H, HindIII; N,
NruI; K, KpnI; X, XhoI.
Fig. 2. Histogram showing the CAT activity in HepG2 and CaCo-2
cell lines directed by various lengths of 5P £anking sequence of the
Apo AIV gene in the presence and absence of the 6-kb 3P £anking
sequence. On the left, representations of the constructs used. On the
right, the corresponding CAT activity obtained. Grey columns indi-
cate basal levels. Black columns indicate the level of expression ob-
tained upon co-transfection with the HNF-4 expression vector. Each
CAT activity represents the mean of at least three separate transfec-
tions.
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stream of the Apo AIV gene but only 1 kb of 3P £anking
sequence [9,13]. We then undertook the study of the presence
of putative long-distance control regions that can in£uence
Apo AIV expression in vivo by introducing the 37+6 Apo
AIV fragment in transgenic mice.
3.2. Human Apo AIV transgenic mice
Three transgenic lines were produced by microinjection of
the 37+6 fragment into fertilised mouse oocytes. The trans-
gene copies were estimated by densitometric measurements of
Southern blot signals (Fig. 3A) and are: line 8021, one copy;
line 8018, nine copies; line 8022, eight copies. All three lines
were found to express human Apo AIV protein in plasma
which was found to be at levels about three times higher
than human levels for the mouse carrying the single copy
and about 11 times for the other two lines (Fig. 3B). Thus,
although not directly related to the gene copy number, an
increase in protein level is observed. A strict correlation of
Apo AIV mRNA and plasma protein levels has not been
observed either in inbred species of mice [8,15] or in all pre-
vious studies of Apo AIV transgenic mice reported. In fact,
DNA, RNA and protein concentrations were shown not to
have a linear correlation perhaps suggesting some form of
post-transcriptional control that modulates secretion and deg-
radation of Apo AIV [13,14].
3.3. Tissue-speci¢c expression of human Apo AIV mRNA in
transgenic mice
A ¢rst analysis of the tissue distribution of Apo AIV
mRNA in wild type (wt) mice, transgenic mouse lines and
human tissues was carried out by Northern blot. Fig. 4A
shows the analysis of mouse wt tissues on a poly(A) com-
mercial membrane (Origene), using a mouse Apo AIV probe.
As expected, liver and small intestine gave a signi¢cant signal,
the small intestine approximately 6-fold higher than in the
liver. A faint but reproducible band was seen in RNA derived
from stomach. No signal was observed by Northern analysis
on total RNA carried out on kidney, heart and lung (data not
shown). Given the levels of expression observed in the wt
tissues the transgenic mouse analysis was carried out using
total RNA derived from the tissues of the three lines and
hybridising with both human and mouse Apo AIV probes
in conditions that only the species-speci¢c signal was detected
(see Section 2). Fig. 4B shows the levels of the endogenous
mouse Apo AIV mRNA for 8018 (similar results were ob-
tained from the other two lines). The normalisation with the
GAPDH and InstantImager quanti¢cation indicates that the
levels in liver and intestine of the mouse Apo AIV mRNA
levels re£ect the ratio observed in wt mice, which is on aver-
age an 8-fold higher expression in intestine than in the liver. A
parallel membrane was hybridised with the human probe (Fig.
4C) and after normalisation with GAPDH the expression of
the human Apo AIV was on average 60-fold higher in intes-
tine than in liver.
It was desirable for a comparative regulatory study to also
have a clear idea of expression of Apo AIV in normal human
tissues. Previous studies [7] had indicated the intestine to liver
ratio of Apo AIV mRNA to be 100:1. In order to con¢rm this
observation we used two pairs of commercial poly(A) blots
that included samples of intestine and liver from di¡erent
individuals. Our results showed that, after normalisation
with GAPDH, whilst in one blot the intestinal/hepatic ratio
of Apo AIV mRNA levels was 1:1 (Fig. 4D), in the second
(Fig. 4E) the expression was exclusively intestinal. Therefore
we could only partially con¢rm the previous studies on human
Apo AIV expression in intestine and liver, making a conclu-
sion about the basal human Apo AIV mRNA levels di⁄cult
to draw. Obviously, these di¡erences in highly standardised
commercial samples are indicative of di¡erent physiological
conditions at the time of sample collection, not to mention
the potential di¡erences in the genetic background. It is inter-
esting to note in Fig. 4E that in the human gastrointestinal
tract expression of Apo AIV mRNA is not detected in the
stomach (as was the case in wt mice, Fig. 4A) and that there
are similar levels in jejunum and ileum. The quantitative PCR
studies in the mouse intestinal tract have shown that the levels
of mouse Apo AIV mRNA detected along the whole small
intestine were comparable (data not shown).
At this point it is clear that in vitro assays or direct tissue
measurements are only indicative. Furthermore, it is well
known that there are considerable variations in Apo AIV
levels due to genetic background and physiological conditions.
It follows that comparison of control elements can only be
achieved using tissues from the same animal expressing both
human and mouse Apo AIV. Therefore the measurement of
human and mouse Apo AIV mRNA levels in the same sample
obtained from a transgenic animal will allow direct compar-
ison since the regulation of the transgene and the endogenous
gene is subjected to the same genetic background and phys-
iological conditions.
3.4. Quantitative PCR measurements
To this end, a detailed study of the tissue-speci¢c expression
of human and mouse Apo AIV was carried out using a pur-
pose-developed competitive quantitative PCR method to
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Fig. 3. A: Quantitative Southern blot analysis of the copy number
of the human Apo AIV transgene present in the three lines. Dilu-
tions of the plasmid corresponding to one and ¢ve copies of the
transgene can be seen on the left. Copies of the transgene in the
transgenic mice were estimated by densitometric scanning and are
eight copies for line 8022, one for line 8021 and nine for line 8018.
B: Human Apo AIV levels in mouse plasma was quanti¢ed by
Western blot. Left, four di¡erent dilutions of a human plasma con-
taining 17 mg/dl of Apo AIV. This is followed by the plasma of a
non-transgenic littermate (3ve) and then four to ¢ve samples for
each transgenic line. The human Apo AIV in the plasma of these
mice was found to be for line 8018 181 þ 30 mg/dl, for line 8021
65 þ 11 mg/dl and for line 8022 202 þ 32 mg/dl.
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measure accurately human and mouse Apo AIV mRNA and
the L-actin mRNA as internal reference. The same Clontech
mRNA sample of the poly(A) blot was used to covalidate
the quantitative PCR method. In fact, the level of Apo AIV
mRNA by the quantitative PCR normalised for 5 pg of L-
actin was 0.6 pg in the intestine and 0.55 pg for the liver, a 1:1
ratio, identical to the one obtained by the Northern blot nor-
malised for equal amounts of GAPDH.
Fig. 5 shows an example of such determinations carried out
in liver and intestine of the 8018 line. The data from all three
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Fig. 4. Characterisation of the expression of the Apo AIV gene was carried out by quantitative Northern blot analysis with both human and
mouse probes that did not cross-react, using the GAPDH mRNA for normalisation. A: Commercially available (Origene) mouse poly(A)
blot, probed with mouse Apo AIV. B: 8018 transgenic mouse RNA probed with mouse Apo AIV probe. C: Identical mRNA used in B,
probed with human Apo AIV probe. D: Commercially available (Clontech) human poly(A) RNA blots, probed with human Apo AIV probe.
E: Commercially available (Invitrogen) human poly(A) blots probed with human Apo AIV probe. Normalisation with GAPDH already per-
formed by the suppliers.
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transgenic lines normalised for 5 pg of L-actin mRNA are
shown in Fig. 5B. In all cases, there are comparable levels
of mouse and human Apo AIV mRNA in liver. In this tissue
the values range from 0.3 to 0.8 pg for the mouse Apo AIV
(the wt being 1.5 pg) and from 0.6 to 1.2 pg for the human
Apo AIV. On the other hand, intestinal Apo AIV mRNA
derived from the endogenous mouse gene was on average
1.18 (range 1^2 pg, wt 3.8 pg). These values were on average
18-fold lower than the human Apo AIV mRNA derived from
the transgene (average 21.6 pg, range 15^27 pg). These results
indicate a di¡erent intestine to liver ratio in the transgene
compared to the endogenous gene, since human Apo AIV
mRNA levels in the intestine are on average 25 times higher
than those observed in the liver. The intestine to liver ratio of
the mouse Apo AIV mRNA levels showed that the intestine
expressed Apo AIV mRNA only three times more than the
liver. These ratios re£ect the results obtained from the North-
ern blot analysis (Fig. 4A,B). Table 1 shows a scheme of the
di¡erent fragments used for producing Apo AIV transgenic
mice with an estimation of the liver and intestinal expression.
Our transgenic di¡ers from those previously reported in the
fact that the hepatic expression of endogenous mouse Apo
AIV mRNA and the human transgene were at comparable
levels. Table 2 shows that in all three transgenic lines the ratio
between human and mouse AIV messenger in liver is 1.5^2.
This indicates an essentially identical hepatic regulation of the
human and mouse Apo AIV expression. In contrast, Table 2
shows that the human intestinal expression is 11^23-fold high-
er than that of the endogenous gene.
In previous human Apo AIV transgenic mouse studies (Ta-
ble 1, construct V) it was reported that no endogenous hepatic
expression was observed. However, the same mouse strains
have been shown to express Apo AIV in the liver [8,28]. These
di¡erences can be explained by the techniques used for
mRNA detection. In fact, in the analysis of the transgenics
derived from construct V, the detection of Apo AIV mRNA
was performed by Northern blot using very high stringency of
hybridisation and short riboprobes to di¡erentiate the human
and mouse RNAs. This procedure obviously lowers the sensi-
tivity of the method and only substantial levels of Apo AIV
mRNA are detected. Construct V gave a signi¢cant human
Apo AIV mRNA signal in the transgenic mouse liver but no
endogenous mouse Apo AIV mRNA was detected. This in-
dicates that the human/mouse liver Apo AIV mRNA ratio
was very high. In the transgenic mice described in this paper
(Table 1, construct VI) we see a human/mouse liver Apo AIV
ratio close to 1:1. Our interpretation is that the absolute levels
of hepatic human Apo AIV mRNA we are seeing are lower
than those seen with transgene derived from construct V and
are then comparable to the endogenous levels in this strain.
This result is then consistent with the inhibitory e¡ect of the
6-kb 3P £anking region observed in vitro in hepatic-derived
cells (Fig. 2A).
In contrast, the intestinal regulation of the transgene did
not follow the pattern observed with the endogenous gene in
the same tissue, possibly requiring regulatory elements in ad-
dition to those present in the 6-kb 3P £anking region that may
be present elsewhere in the 17-kb locus spanning the AI-CIII-
AIV gene cluster. Alternatively, our results could indicate that
the transgene includes a set of cis-acting elements that pro-
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Table 2
Ratios of human intestine/mouse intestine and human liver/mouse
liver using the mean values obtained from the quantitative PCR
8018 8021 8022
H.In/M.In 23.00 18.30 11.00
H.Li/M.Li 2.00 1.50 2.00
Table 1
Scheme of previous constructs used in the production of human Apo AIV transgenic mice with an estimate of the expression of the transgene
Constructs I^IV [9] ; construct V [13]; construct VI, this paper.
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duce the accepted human pattern of expression to be domi-
nant in mice, or that the human cis-acting elements are im-
properly recognised by the mouse trans-acting factors. The
distribution of human Apo AIV mRNA in our mouse model
is qualitatively similar to that of the accepted pattern in hu-
man with only very slight alteration of the endogenous mouse
Apo AIV mRNA levels. We are currently using these trans-
genic lines to elucidate the mechanism by which the elements
dispersed throughout the cluster are activated or inhibited by
the action of natural or therapeutic e¡ectors in vivo, a subject
of great interest considering the anti-atherogenic action of the
Apo AIV protein. Our mouse model thus provides an excel-
lent substrate to design therapeutic protocols for those meta-
bolic derangements that bene¢t from variations in Apo AIV
levels.
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